June 29, 2018
CHMP recommends approval of Sanofi’s Cablivi
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Cablivi (caplacizumab) in Europe…
Pharmaceuticals, Biotechnology and Life Sciences
Category: Approval
June 29, 2018
Novartis aims at spinoff of Alcon eye care devices business
Novartis on Friday said it intends to spinoff Alcon, its eye care division, into a separately-traded standalone company, which would…
June 28, 2018
Sanofi and Advent in negotiations for €1.9 billion acquisition of Zentiva
Sanofi and Advent International have finished negotiations for the acquisition of Zentiva, Sanofi’s European generics business, by Advent and the…
June 28, 2018
Better prevention can curbe significant disruption to daily life and work caused by migraine
Novartis and the European Migraine and Headache Alliance (EMHA) Wednesday presented initial findings from the largest global migraine patient study…
June 27, 2018
Lynparza significantly delays disease progression in Phase III 1st-line SOLO-1 trial for ovarian cancer
AstraZeneca and Merck’s Phase III SOLO-1 trial of Lynparza (olaparib) tablets, for women with BRCA-mutated (BRCAm) advanced ovarian cancer treated…
June 27, 2018
Symcel appoints two new board members to bolster R&D business growth and expansion into the clinical diagnostics market
Symcel said Wednesday it has appointed two new board members; Erik Walldén and Stefan Löfås, who are expected to play a…
June 27, 2018
Servier, Galapagos kick off therapeutic candidate phase 2 trial for knee osteoarthritis patients
Servier and Galapagos NV have started a global Phase 2 trial with S201086/GLPG1972 in knee osteoarthritis patients, titled Roccella, in…
June 26, 2018
Long way for psoriasis patients despite clear or almost clear skin being more achievable
The impact of psoriasis is more than skin deep and can have a profound effect on people’s physical and emotional…
June 25, 2018
Former TiGenix CEO to lead Nordic Nanovector from July
Nordic Nanovector has appointed Vivet Therapeutic’s chairman and former TiGenix’s CEO, Eduardo Bravo as its new Chief Executive Officer, the…
June 25, 2018
Jardiance reduced risk of kidney disease progression in adults with type 2 diabetes
Boehringer Ingelheim and Eli Lilly have shown consistent effects for Jardiance versus placebo on renal outcomes in patients with established…